EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.
评估两类不同类型的化合物(STAT3 抑制剂和 Serms)预防膀胱癌的作用。
基本信息
- 批准号:10674662
- 负责人:
- 金额:$ 24.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-21 至 2024-02-01
- 项目状态:已结题
- 来源:
- 关键词:AffinityAnimalsApoptosisBiological MarkersBladder NeoplasmCell ProliferationCell SurvivalChemopreventive AgentDevelopmentDiseaseDominant-Negative MutationDoseEstradiolEstrogen Receptor ModulatorsEstrogen Receptor alphaEstrogen Receptor betaEstrogen ReceptorsFamilyImmune responseIn VitroIncidenceMalignant NeoplasmsMalignant neoplasm of urinary bladderMethylnitrosoureaModelingMusMuscleNitrosaminesNormal CellOrganPatientsPreventionProcessRattusRecurrenceReportingResearchRodent ModelRoleSelective Estrogen Receptor ModulatorsStat3 proteinSupporting CellTissue SampleTravelUnited StatesUrinary systemanalogbladder cancer preventioncancer typecarcinogenesisefficacy testinginhibitormalignant breast neoplasmmembernovelpharmacodynamic biomarkerpreventive interventionreceptorresearch and developmentstatisticstranscription factortumor
项目摘要
Urinary bladder cancer is one of the most prevalent malignancies of the urinary system, with over 80,000 new cases predicted in the United States in 2019 (https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html). Although 70% of patients initially present with non-muscle-invasive disease, urinary bladder tumors have a high rate of recurrence (50 –70%), and 10-15% will progress to muscle-invasive disease within a 5-year period, making the prevention of bladder cancer an important priority. Throughout the years, a relatively large number of compounds have been tested for efficacy in the prevention of early stage bladder cancers. However, many of these agents have proven to be largely ineffective or toxic to various organs. Thus, there is a need for the identification of new chemopreventive agents with novel mechanisms of action.
Estrogen receptor α (ERα) is expressed in 18% of patients with bladder cancer and is associated with highly proliferative tumors and lower overall survival; ERβ is expressed in 63% of bladder cancer tumors, and the degree of ERβ expression increases with increasing stage and grade of differentiation. These correlations, combined with the findings that N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)-treated mice lacking ERβ have a reduced incidence of bladder cancer, suggest that the ER could serve as a target for preventive intervention. In support of this, several groups have reported that estrogen receptor modulators reduce bladder cancer cell proliferation in vitro, and reduce cancer incidence in BBN-treated mice. This Task Order will evaluate the selective estrogen receptor modulator bazedoxifene for bladder cancer prevention. Bazedoxifene has affinity for both the ERα and ERβ receptors, and it is a competitive inhibitor of 17-β-estradiol at either estrogen receptor. It is also highly effective as a chemopreventive agent in the N-Nitroso-N-methylurea (MNU)-rat model, in which breast cancer development is driven by expression of the ER.
Signal transducer and activator of transcription 3 (STAT3) is one of the seven members of a family of transcription factors that regulates cell proliferation, differentiation, apoptosis, and the immune response. Although the activation of STAT3 is transient and highly regulated in normal cells, it is constitutively active in several types of cancer, including bladder cancer. The findings that the expression of dominant-negative STAT3 inhibits bladder tumor formation and that the STAT3 inhibitor WP1066 reduces cell survival and proliferation of bladder cancer cells support a role for STAT3 in bladder cancer carcinogenesis and suggest that STAT3 could serve as a target for preventive intervention. This Task Order will also investigate the chemopreventive potential of STAT3 inhibitors such as GLG-302,SH5-07, YHO-1701, C188-9, and others that are in the process of being developed by the Chemopreventive Agent Development Research Group.
膀胱癌是最常见的泌尿系统恶性肿瘤之一,预计2019年美国将有超过80,000例新病例。(https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html).虽然70%的患者最初表现为非肌肉侵袭性疾病,但膀胱肿瘤的复发率很高(50%-70%),10%-15%的患者将在5年内进展为肌肉侵袭性疾病,这使得预防膀胱癌成为重要的优先事项。多年来,已有相当数量的化合物在预防早期膀胱癌方面进行了有效性测试。然而,其中许多药物已被证明在很大程度上是无效的或对各种器官有毒。因此,有必要确定具有新的作用机制的新的化学预防药物。
雌激素受体α(ERα)在18%的膀胱癌患者中表达,与高增殖性肿瘤和低总生存率有关;ERβ在63%的膀胱癌患者中表达,且ERβ的表达程度随分化程度和分期的增加而增加。这些相关性,再加上N-丁基-N-(4-羟基丁基)-亚硝胺(BBN)处理的缺乏ERβ的小鼠膀胱癌发病率降低的发现,表明ER可以作为预防干预的目标。为了支持这一点,几个小组已经报道了雌激素受体调节剂在体外减少膀胱癌细胞的增殖,并降低了BBN治疗的小鼠的癌症发病率。该任务顺序将评估选择性雌激素受体调节剂巴多昔芬预防膀胱癌。巴多昔芬对ERα和ERβ受体均有亲和力,是17-β-雌二醇在这两种受体上的竞争性抑制剂。在N-亚硝基-N-甲基脲(MNU)-大鼠模型中,它也是一种高效的化学预防药物,在该模型中,乳腺癌的发生是由ER的表达驱动的。
信号转导和转录激活因子3(STAT3)是调控细胞增殖、分化、凋亡和免疫反应的转录因子家族的7个成员之一。虽然STAT3的激活在正常细胞中是短暂的,并且受到高度调控,但它在包括膀胱癌在内的几种类型的癌症中都是结构性活跃的。研究结果表明,显性负性STAT3的表达抑制了膀胱癌的形成,STAT3抑制剂WP1066降低了膀胱癌细胞的存活和增殖,支持了STAT3在膀胱癌发生中的作用,提示STAT3可以作为预防干预的靶点。该任务令还将调查STAT3抑制剂的化学预防潜力,如GLG-302、SH5-07、YHO-1701、C188-9,以及化学预防药物开发研究组正在开发的其他药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chinthalapally V. Rao其他文献
Mutational disparities in colorectal cancers of White Americans, Alabama African Americans, And Oklahoma American Indians
白种美国人、阿拉巴马州非裔美国人和俄克拉何马州美洲印第安人结直肠癌的突变差异
- DOI:
10.1038/s41698-024-00782-9 - 发表时间:
2024-12-23 - 期刊:
- 影响因子:8.000
- 作者:
Hiroshi Y. Yamada;Madhusmita Rout;Chao Xu;Philip H. O’Neill;Farrukh Afaq;Katherine T. Morris;Dharambir K. Sanghera;Upender Manne;Chinthalapally V. Rao - 通讯作者:
Chinthalapally V. Rao
Targeting PGE<sub>2</sub>/IL-23 Nexus in TME for CRC Prevention and Treatment
- DOI:
10.1016/j.canlet.2023.216553 - 发表时间:
2024-01-28 - 期刊:
- 影响因子:
- 作者:
Chinthalapally V. Rao - 通讯作者:
Chinthalapally V. Rao
Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer
- DOI:
10.1007/s10555-011-9311-2 - 发表时间:
2011-10-21 - 期刊:
- 影响因子:8.700
- 作者:
Naveena B. Janakiram;Altaf Mohammed;Chinthalapally V. Rao - 通讯作者:
Chinthalapally V. Rao
Chinthalapally V. Rao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chinthalapally V. Rao', 18)}}的其他基金
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTIO
预防癌症临床前药物开发计划:临床前疗效和终点生物标志物。
- 批准号:
10269136 - 财政年份:2020
- 资助金额:
$ 24.41万 - 项目类别:
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.
评估两类不同类型的化合物(STAT3 抑制剂和 Serms)预防膀胱癌的作用。
- 批准号:
10269139 - 财政年份:2020
- 资助金额:
$ 24.41万 - 项目类别:
ShEEP Request for CTL ImmunoSpot S6 Universal Analyzer
ShEEP 请求 CTL ImmunoSpot S6 通用分析仪
- 批准号:
9795713 - 财政年份:2019
- 资助金额:
$ 24.41万 - 项目类别:
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS
通过 iNOS 和 COX-2 选择性抑制剂预防 CRC
- 批准号:
6815750 - 财政年份:2004
- 资助金额:
$ 24.41万 - 项目类别:
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS
通过 iNOS 和 COX-2 选择性抑制剂预防 CRC
- 批准号:
6952292 - 财政年份:2004
- 资助金额:
$ 24.41万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 24.41万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 24.41万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 24.41万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 24.41万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 24.41万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 24.41万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 24.41万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 24.41万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 24.41万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 24.41万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)